Looking for effective medicines to manage seizures? Brivaracetam is one of the newest antiepileptic drugs that has been gaining attention in recent years. With its unique mechanism of action and promising results, this drug has emerged as a potential game-changer in the field of epilepsy management. In this blog post, we will provide you with an overview of brivaracetam's mechanism and efficacy for medical professionals to help you understand why it could be a valuable addition to your arsenal against seizures. So, whether you're new to the world of epilepsy treatment or looking for ways to enhance your current approach, keep reading!
Brivaracetam (brand name Briviact) is a newer anti-seizure medication that was first approved by the FDA in 2016. It is structurally similar to levetiracetam (Keppra), but has a different mechanism of action. Brivaracetam binds to the synaptic vesicle protein 2A (SV2A) in the brain, which is thought to modulate neurotransmission and reduce seizure activity. Clinical studies have shown brivaracetam to be effective in reducing seizure frequency in people with partial-onset seizures and secondarily generalized seizures. It is typically well-tolerated, with the most common side effects being dizziness, insomnia, and headache. Brivaracetam may be used as monotherapy or adjunctive therapy for seizure control in adults and children over the age of 4 years.
Brivaracetam (BAN) is a new anticonvulsant drug that has shown efficacy in treating partial seizures both in adults and children. The precise mechanism of action of BAN is not known, but it is thought to act on SV2A, a protein involved in the regulation of neurotransmitter release. BAN has a high binding affinity for SV2A, which may explain its anticonvulsant effects. In addition to its effect on SV2A, BAN also modulates GABAergic and glutamatergic transmission. These mechanisms likely contribute to the efficacy of BAN in treating partial seizures. In clinical trials, BAN has been shown to be effective in reducing seizure frequency and severity in patients with partial seizures. The most common side effects of BAN include dizziness, somnolence, headache, nausea, and vomiting. These side effects are generally mild and resolve with continued use of the medication.
One of the most common side effects of brivaracetam is dizziness. Other side effects include: Nausea, Headache, Vomiting, Irritability, Diarrhea, Weight loss. These side effects are typically mild and go away on their own. Medical professionals may be able to adjust dosage or prescribe a different medication.
Brivaracetam (brand name Briviact) is a medication used to treat epilepsy. It is classified as a selective vinylogous amide and acts as an anticonvulsant by binding to the SV2A protein in the brain. The precise mechanism by which it prevents seizures is not fully understood, but it is thought to involve modulation of synaptic transmission. Brivaracetam has been shown to be effective in reducing seizure frequency in both adults and children with epilepsy, and has a good safety profile.
Brivaracetam (Briviact) is a newer generation antiepileptic medication that was first approved by the FDA in 2016. It has a similar chemical structure to levetiracetam (Keppra) and shares many of the same benefits. Brivaracetam has been shown to be effective in reducing seizure frequency in people with epilepsy, both as monotherapy and in combination with other antiepileptic drugs. Brivaracetam is most commonly used to treat focal onset seizures, but can also be used to treat generalized onset seizures. The recommended starting dose is 50 mg twice daily, but this may be increased or decreased depending on the individual's response. Brivaracetam is available as tablets, oral solution, and injection. Like other antiepileptic drugs, brivaracetam may cause side effects such as drowsiness, dizziness, headache, nausea, and vomiting. These side effects are usually mild and go away with time. More serious side effects are rare but may include allergic reactions, changes in vision, difficulty breathing, and depression.
In conclusion, brivaracetam is an antiepileptic medication with a unique mechanism of action that offers improved seizure control for patients. It has been proven to be safe and effective in adults and adolescents aged 16 years or older, as well as in pediatric patients aged 2–16 years old. Brivaracetam has fewer drug-drug interactions than other antiepileptics and may provide additional benefits such as improved cognition. Medical professionals can refer to this article when discussing treatment options with their patients who have epilepsy or seizures.
1.
The way that miR-377 inhibits cells that cause prostate cancer.
2.
Five new papers highlight cancer inequities, challenges and opportunities in South Asia
3.
The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.
4.
What Dolph Lundgren's journey from terminal diagnosis to 'cancer free' can tell us about cancer care
5.
Survivors of childhood brain cancer are more likely to be held back in school
1.
Precision Era in Pediatric Oncology, from Genomic Breakthroughs to Lifelong Learning
2.
Fibroma: Understanding the Causes, Symptoms, and Treatment Options
3.
Navigating the Evolving Landscape of Oncology Clinical Trials in the Era of Precision Medicine
4.
The Importance of Early Detection in Angiosarcoma: A Story of Survival
5.
Impact of Hormone Therapy Cessation on Tumor Growth: Case Study of Ki-67 Reduction
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation